Recent Breakthroughs and Emerging Trends in Gullain Barre Syndrome

Ms. E. Honey, C. Prapulla

Pharmacology, Dr. Kv Subbareddy Institute of Pharmacy, Kurnool District Dupadu, Andhra Pradesh, India

DOI: https://doi.org/10.51244/IJRSI.2025.1210000085

Received: 18 October 2025; Accepted: 24 October 2025; Published: 05 November 2025

ABSTRACT

Guillain-Barré Syndrome (GBS) is an acute autoimmune polyneuropathy causing progressive weakness, loss of reflexes, and sensory or autonomic dysfunction. It often follows Campylobacter jejuni infection due to molecular mimicry between microbial and nerve antigens. GBS affects 1–2 per 100,000 people annually, mainly males and older adults. Subtypes include AIDP, AMAN, AMSAN, and Miller Fisher syndrome. Diagnosis relies on clinical signs, CSF analysis, and nerve conduction studies. Early treatment with IVIG or plasma exchange improves outcomes, though some patients face lasting disability or death. Supportive care, physiotherapy, and new immunotherapies enhance recovery, while infection prevention helps reduce risk.

Keywords: Polyneuropathy, Acute flaccid paralysis, Autoimmune response, Camphylobacter jejuni.

INTRODUCTION

Guillain-Barré Syndrome (GBS) is an acute autoimmune polyneuropathy causing progressive weakness that peaks within four weeks. First described by Guillain, Barré, and Strohl in 1916, it remains the leading cause of acute flaccid paralysis worldwide, affecting 1–2 people per 100,000 annually, more often males and older adults. In most cases, GBS follows a respiratory or gastrointestinal infection, commonly due to *Campylobacter jejuni*, *Cytomegalovirus*, Zika virus, or SARS-CoV-2, through molecular mimicry between microbial and nerve antigens. Major subtypes include AIDP, AMAN, AMSAN, and Miller Fisher syndrome. Diagnosis is based on clinical findings, cerebrospinal fluid analysis, and electrophysiological tests. Although most patients respond to intravenous immunoglobulin or plasma exchange, 3–10% may die and about 20% experience residual disability. Ongoing research on complement inhibitors and other immunotherapies shows promise for improved outcomes.



FIG:1 Guillain Barre syndrome

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Epidemiology:

Table 1: Summary related to epidemiology of GBS

PARAMETER	DATA\FINDINGS
Annual incidence	1.3cases per 100,000
Age distribution	Elder people are at higher risk
Sex ratio	Males>females (1.5-1.7:1)
Seasonal trend	May increases in certain seasons like (rainy)
Infections	Intestinal infection, respiratory tract infection, campylobacter jejuni
Major variants	AIDP, AMAN

Pathophysiology:

Immune system launches an attack against the peripheral nervous system.

The triggering events begin with infection or vaccination.

The immune system fails to protect against self-tissues because of immunological self-tolerance failure.

The disease produces damage to the protective myelin sheath while also damaging axonal structures during the demyelinating process, and T-Helper cells produce cytokines.

The immune system produces antibodies which target gangliosides to combat bacterial infections.

The development of disorders at motor nerve terminals and nodes of Ranvier depends on the essential function of antibiotics.

The complement system becomes active through this process. The disease first attacks the peripheral nervous system.

This leads to both functional decline and physical harm to the nerves.

The condition produces two main types of nerve damage, which include axonal degeneration and segmental demyelination.

The antibodies bind at motor nerve terminals, which blocks the release of ACH and stops nerve conduction.

The condition results in conduction block because of membrane damage. The damage process activates both calcium influx and the complement cascade.

The process leads to proteolytic enzyme activation, which includes calpins and caspases.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Axonal degeneration occurs.

Research shows that GM1 antibodies have the ability to attack Glial cells.

The damage to Schwann cells leads to axonal degeneration through a secondary process.

The deterioration of demyelization and axonal damage occurs.



FIG:2 Pathophysiology of GBS

Types Of Guillain Barre Syndrome:

GBS has four main subtypes: AIDP, MFS, AMAN**,** and AMSAN**.**

AIDP is the most common form (85–90% of cases) and involves demyelination of peripheral nerves, causing muscle weakness, sensory loss, and complications such as irregular heartbeat or respiratory failure.

MFS mainly affects cranial nerves, leading to double vision, unsteady gait, and facial weakness; it is linked to anti-GQ1b antibodies.

AMAN damages motor nerve axons, producing severe muscle weakness with minimal sensory loss, often seen in children and young adults.

AMSAN affects both motor and sensory nerves, resulting in marked weakness and poor recovery.

Diagnostic Criteria:

When to Suspect:

Rapidly progressive limb weakness, reduced reflexes, sensory loss, facial or swallowing weakness, and eye movement problems.

Diagnosis:

Based on clinical features, CSF analysis (high protein with normal cell count), and nerve conduction studies after excluding other causes.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

ICU Admission:

Required for rapid progression, autonomic instability, swallowing, or breathing difficulty.

Treatment:

IV immunoglobulin (IVIG) or plasma exchange.

Early Complications:

Arrhythmias, infections, pain, urinary retention, constipation, eye problems, hyponatremia, pressure sores, and muscle stiffness.

When to Start Treatment:

If unable to walk 10 m unaided, or if weakness, autonomic, or respiratory issues worsen.

Monitoring:

Regularly assess muscle strength, respiration, blood pressure, heart rhythm, and swallowing.

Treatment Fluctuation:

Repeat IVIG or plasma exchange if symptoms recur.

Pharmacological Approaches



FIG:4 Treatment for GBS

Plasma Exchange (PE): Removes harmful antibodies from plasma, speeding recovery and reducing ventilation needs, especially if started within 2 weeks. Standard regimen: 5 sessions over 2 weeks. Rare risks: sepsis, viral infections [28,29].

Immunotherapy (IVIG): IV immunoglobulins neutralize antibodies and accelerate recovery when started early after motor symptoms. Mild cases may not need IVIG [30,31].

Mechanical Ventilation: Needed in ~25% of patients with respiratory failure, rapid progression, bulbar involvement, or autonomic dysfunction. ICU support and monitoring are crucial for positive outcomes [32].

MEDICATIONS:

- NSAIDs (ibuprofen, naproxen) – relieve mild muscle/joint pain.
- Opioids – for severe pain; risk of side effects and dependency.
- Gabapentin – reduces nerve pain by inhibiting excitatory neurotransmitter release.
- Carbamazepine – eases nerve pain by blocking sodium channels and reducing nerve signalling.
- Tricyclic antidepressants (e.g., amitriptyline) – relieve pain and improve mood by increasing serotonin and norepinephrine.
- Additional care – blood clot prevention in immobile or paralyzed patients.

Non- Pharmalogical Approaches

- Rehabilitation**:** Physical and occupational therapy maintain flexibility, prevent complications, and restore muscle function.
- Strengthening**:** Resistance training or weights to improve muscle power.
- Aerobic training**:** Walking or cycling 2–3 times/week for stamina and cardiovascular health.
- Flexibility/stretching**:** Maintain joint mobility and prevent stiffness.
- Gait training**:** Improve walking patterns using parallel bars or treadmills.
- Exercise monitoring**:** High-intensity exercise can boost recovery but must avoid overworking partially denervated muscles [36,40].

Future Perspective For Gbs:

Targeting complement activation is a promising new strategy for GBS. Current therapies under trial include anti-C1q antibodies (Phase 1b, NCT04035135) and IgG-degrading enzymes (Ides) (Phase 2, NCT01582763) [31–35]. These approaches may help prevent serious and long-term neurological complications.

Etiological Factors Of Guillain Barre Syndrome:

GBS occurs when the immune system attacks peripheral nerves, causing muscle weakness and sensory loss. Common triggers include bacterial infections *(*Campylobacter*,* Mycoplasma*),* viral infections (Influenza, CMV, EBV, Zika, Hepatitis, HIV), surgery**,** trauma, and rarely vaccinations [10–12,22,33].



FIG:5 Etiological factors of GBS

Management Of Gulliain Baree Syndrome:

- Monitoring**:** Stable patients walking >5 m can be managed locally but need close observation of disease progression, vitals, and respiratory function.
- Supportive Care**:** Essential to reduce mortality from complications.
- Immunotherapy**:** IVIG or plasma exchange within the first weeks improves recovery, reduces ventilator need, and enhances long-term muscle strength. PE sessions should match severity (mild 2, moderate 4, severe 4), with small-volume PE used in resource-limited settings.
- DVT Prophylaxis**:** Subcutaneous heparin and compression stockings; oral anticoagulants for prolonged immobility or tracheostomy
- Pain Management**:** Opioids, gabapentin, carbamazepine, NSAIDs, acetaminophen, or tricyclic antidepressants; monitor for sedation and bowel issues.

Prevention Of Gullain Barre Syndrome:

While GBS is largely unpreventable, risk can be reduced by:

- Practicing good hygiene (handwashing, disinfecting surfaces, avoiding contact with sick individuals)
- Following food safety (thoroughly cook poultry, avoid unpasteurized milk, wash fruits/vegetables)
- Staying healthy (balanced diet, regular exercise, hydration)
- Keeping vaccinations up to date and seeking early treatment for infections [12,17,28,33,40]

FIG:6 Prevention for GBS

Complications:

- Respiratory failure**:** Weakness may require ventilation (~22% of patients).
- Residual weakness or numbness may persist.
- Cardiovascular issues**:** Blood pressure changes, irregular heartbeat.

- Nerve pain affects ~1/3 of patients.
- Bowel/bladder dysfunction and blood clots from immobility.
- Pressure sores from limited movement; prevent with repositioning [7,23,24,27].



FIG:7 Complications of GBS

CONCLUSION

Guillain-Barré Syndrome (GBS) is a serious autoimmune disorder and a leading cause of acute flaccid paralysis. While infections and molecular mimicry play key roles, early diagnosis via CSF analysis and nerve studies improves outcomes. Main treatments include IVIG and plasma exchange, though many patients still face disability, emphasizing the importance of rehabilitation and supportive care. Emerging therapies, like complement inhibitors, offer future promise. Prevention, early intervention, and multidisciplinary management are essential to reduce morbidity and mortality.

REFERENCES

1. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123–133.
2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–727.
3. Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–482.
4. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(S1): S21–24.
5. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366(24):2294–2304.
6. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063.
7. Hughes RAC, Wijdicks EFM, Benson E, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome. Neurology. 2003;61(6):736–740.
8. Hadden RDM, Cornblath DR, Hughes RAC, et al. Electrodiagnostic criteria for Guillain-Barré syndrome: a consensus statement. Ann Neurol. 1998;44(5):780–788.
9. Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol. 2013;12(12):1180–1188.
10. Jacobs BC, Rothbarth PH, van der Meché FGA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110–1115.

11. Wakerley BR, Uncini A, Yuki N. Guillain-Barré and Miller Fisher syndromes—new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–544.
12. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–683.
13. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214–1228.
14. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33(4):333–342.
15. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal–cervical–brachial variant of Guillain–Barré syndrome. Arch Neurol. 2007;64(10):1519–1523.
16. Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491–510.
17. Hughes RAC, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130(9):2245–2257.
18. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349(9047):225–230.
19. Lawn ND, Wijdicks EFM. Fatal Guillain-Barré syndrome. Neurology. 1999;52(3):635–638.
20. Dhar R, Stitt L, Hahn AF. The morbidity and outcome of Guillain-Barré syndrome associated with mechanical ventilation. Can J Neurol Sci. 2008;35(4):443–446
21. Sri Ramachandra M, Kavya G, Vijay Teja V, Irshad S. A review on Guillain–Barre syndrome. Int J Adv Pharm Sci (IAJPS). 2025;12(8):7-13.